Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease

被引:0
|
作者
Giovanni Corsetti [1 ]
Evasio Pasini [2 ]
Tiziano M Scarabelli [3 ,4 ]
Claudia Romano [1 ]
Pratik R Agrawal [3 ]
Carol ChenScarabelli [5 ]
Richard Knight [4 ]
Louis Saravolatz [4 ]
Jagat Narula [3 ]
Mario FerrariVivaldi [6 ]
Vincenzo Flati [7 ]
Deodato Assanelli [8 ]
Francesco S Dioguardi [9 ]
机构
[1] Department of Clinical & Experimental Sciences,Division of Human Anatomy & Physiopathology,University of Brescia
[2] "SMaugeri Foundation",IRCCS,Cardiology Division,Medical Centre of Lumezzane
[3] Zena and Michael A,Wiener Cardiovascular Institute,Mount Sinai Medical Center
[4] Center for Heart and Vessel Preclinical Studies,StJohn Hospital & Medical Center,Wayne State University School of Medicine
[5] VA Ann Arbor Health Care System,University of Michigan
[6] Department of Cardiovascular Surgery,"San Rocco" Hospital
[7] Department of Biotechnological and Applied Clinical Sciences,University of L'Aquila
[8] Division of Sport-Internal Medicine,Department of Clinical & Experimental Sciences,University of Brescia
[9] Department of Clinical Sciences and Community Health,University of
关键词
D O I
暂无
中图分类号
R54 [心脏、血管(循环系)疾病];
学科分类号
摘要
Background Klotho proteins(α-and β) are membrane-based circulating proteins that regulate cell metabolism,as well as the lifespan modulating activity of Fibroblast Growth Factors(FGFs).Recent data has shown that higher plasma circulating Klotho levels reduce cardiovascular risk,suggesting Klotho has a protective role in cardiovascular diseases.However,although so far it has been identified in various organs,it is unknown whether cardiomyocytes express Klotho and FGFs,and whether high cardiovascular risk could affect cardiac expression of Klotho,FGFs and other molecules.Methods We selected 20 patients with an estimated 10-year high atherosclerotic cardiovascular disease and 10 age-matched control subjects with an estimated 10-year low risk undergone cardiac surgery for reasons other than coronary artery by-pass.In myocardial biopsies,we evaluated by immuno-histochemistry whether Klotho and FGFs were expressed in cardiomyocytes,and whether higher cardiovascular risk influenced the expression of other molecules involved in endoplasmic reticulum stress,oxidative stress,inflammation and fibrosis.Results Only cardiomyocytes of patients with a higher cardiovascular risk showed lower expression of Klotho,but higher expressions of FGFs.Furthermore,higher cardiovascular risk was associated with increased expression of oxidative and endoplasmic reticular stress,inflammation and fibrosis.Conclusions This study showed for the first time that Klotho proteins are expressed in human cardiomyocytes and that cardiac expression of Klotho is down-regulated in higher cardiovascular risk patients,while expression of stress-related molecules were significantly increased.
引用
收藏
页码:701 / 711
页数:11
相关论文
共 50 条
  • [1] Decreased expression of Klotho in cardiac atria biopsy samples from patients at higher risk of atherosclerotic cardiovascular disease
    Corsetti, Giovanni
    Pasini, Evasio
    Scarabelli, Tiziano M.
    Romano, Claudia
    Agrawal, Pratik R.
    Chen-Scarabelli, Carol
    Knight, Richard
    Saravolatz, Louis
    Narula, Jagat
    Ferrari-Vivaldi, Mario
    Flati, Vincenzo
    Assanelli, Deodato
    Dioguardi, Francesco S.
    JOURNAL OF GERIATRIC CARDIOLOGY, 2016, 13 (08) : 701 - 711
  • [2] Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD
    Lidgard, Benjamin
    Zelnickv, Leila
    Anderson, Amanda H.
    Feldman, Harold
    Go, Alan
    He, Jiang
    Kansal, Mayank
    Mohanty, Madhumita Jena
    Mehta, Rupal
    Shlipak, Michael G.
    Soliman, Elsayed
    Weir, Matt R.
    Bansal, Nisha
    KIDNEY360, 2022, 3 (05): : 859 - 871
  • [3] ECONOMIC BURDEN OF DIABETIC PATIENTS WITH ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR RISK FACTORS FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Marcellusi, A.
    Sciattella, P.
    Bini, C.
    Rotundo, M.
    Aimaretti, G.
    Mennini, F. S.
    VALUE IN HEALTH, 2020, 23 : S509 - S509
  • [4] Relationship between the risk of atherosclerotic cardiovascular disease and decreased functional bladder capacity
    Madani, Ali Hamidi
    Bateni, Bahador Heidari
    Pourrajabi, Aseme
    Leyli, Ehsan Kazemnezhad
    Madani, Mohammad Hamidi
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025, 57 (03) : 709 - 713
  • [5] Cardiovascular imaging for the assessment of atherosclerotic disease: Implications for cardiac risk stratification
    Makaryus A.N.
    Current Cardiovascular Risk Reports, 2008, 2 (2) : 107 - 112
  • [6] Risk of Atherosclerotic Cardiovascular Disease in Patients With Bipolar Disorder and Accuracy of a Cardiovascular Risk Calculator
    Foroughi, Moein
    Medina-Inojosa, Jose R.
    Lopez-Jimenez, Francisco
    Saeidifard, Farzane
    Viniciguerra, Manlio
    Frye, Mark A.
    Morgan, Robert J.
    BIOLOGICAL PSYCHIATRY, 2018, 83 (09) : S283 - S283
  • [7] Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
    Li, Sha
    Liu, Hui-Hui
    Guo, Yuan-Lin
    Zhu, Cheng-Gang
    Wu, Na-Qiong
    Xu, Rui-Xia
    Dong, Qian
    Qian, Jie
    Dou, Ke-Fei
    Li, Jian-Jun
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [8] Hypoglycemia and Risk of Atherosclerotic Cardiovascular Disease (ascvd) in Patients With Diabetes
    Rana, Jamal S.
    Liu, Jennifer Y.
    Moffet, Howard H.
    Karter, Andrew
    CIRCULATION, 2020, 142
  • [9] Severe Hypoglycemia and Risk of Atherosclerotic Cardiovascular Disease in Patients With Diabetes
    Rana, Jamal S.
    Moffet, Howard H.
    Liu, Jennifer Y.
    Karter, Andrew J.
    DIABETES CARE, 2021, 44 (03) : E40 - E41
  • [10] Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease
    Zhao, Yanglu
    Xiang, Pin
    Coll, Blai
    Lopez, J. Antonio G.
    Wong, Nathan D.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (03)